https://orcid.org/0000-0003-3323-6637
References
- Patil TS, Deshpande AS. Innovative strategies in the diagnosis and treatment of tuberculosis: a patent review (2014–2017). Expert Opin Ther Pat. 2018;28(8):615–623.
- Patil TS, Deshpande AS, Deshpande S, et al. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need. J Drug Target. 2019;27(1):12–27.
- Global Tuberculosis Report; 2016; [Internet]. Geneva, Switzerland: World Health Organization; [cited 2020 Jul 19]. p. 1–201. Available from: https://apps.who.int/iris/handle/10665/250441
- Patil TS, Deshpande AS. Nanostructured lipid carriers-based drug delivery for treating various lung diseases: a state-of-the-art review. Int J Pharm. 2018;547(1–2):209–225.
- Patil TS, Deshpande AS. Mannosylated nanocarriers mediated site-specific drug delivery for the treatment of cancer and other infectious diseases: a state of the art review. J Control Release. 2020;320:239–252.
- Patil TS, Deshpande AS, Deshpande S. Critical review on the analytical methods for the estimation of clofazimine in bulk, biological fluids and pharmaceutical formulations. Crit Rev Anal Chem. 2018;48(6):492–502.
- Global Tuberculosis Report; 2019; [Internet]. Geneva, Switzerland: World Health Organization; [cited 2020 Jul 19]. p. 1–283. Available from: https://www.who.int/tb/publications/global_report/en/
- Patil-Gadhe A, Kyadarkunte A, Patole M, et al. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. Eur J Pharm Biopharm. 2014;88(1):169–177.
- Patil TS, Deshpande AS. Design, development, and characterization of clofazimine-loaded mannosylated nanostructured lipid carriers: 33-Box–Behnken design approach. Mater Technol. 2020;1–16.
- Mukherjee KL, Ghosh S. Medical laboratory technology. 2nd ed. New Delhi: Tata McGraw-Hill Publishing Company; 1988.
- Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148(3):359–367.
- Patil TS, Deshpande AS, Deshpande S, et al. Evaluation of nanocarrier-based dry powder formulations for inhalation with special reference to anti-tuberculosis drugs. Crit Rev Ther Drug Carrier Syst. 2019;36(3):239–269.
- Test no. 403: acute inhalation toxicity, organization for economic co-operation and development (OECD). OECD Guidelines for the Testing of Chemicals; 2009. p. 1–19. Available from: https://read.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en#
- Draft guidance document on inhalation toxicity testing 39. Organization for Economic Co-operation and Development (OECD); 2017. p. 1–110. Available from: https://www.oecd.org/env/ehs/testing/DRAFT%20GD39%202ndWNTCR2017.pdf
- Patil TS, Deshpande AS. Development of an innovative quality by design (QbD) based stability-indicating HPLC method and its validation for clofazimine from its bulk and pharmaceutical dosage forms. Chromatographia. 2019;82(2):579–590.
- Nimje N, Agarwal A, Saraogi GK, et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target. 2009;17(10):777–787.
- Sahu PK, Mishra DK, Jain N, et al. Mannosylated solid lipid nanoparticles for lung-targeted delivery of paclitaxel. Drug Dev Ind Pharm. 2015;41(4):640–649.
- Patil-Gadhe A, Pokharkar V. Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: optimization by factorial design. Int J Pharm. 2016;501(1–2):199–210.